<DOC>
	<DOCNO>NCT01395953</DOCNO>
	<brief_summary>The main objective exploratory 8 week pilot study evaluate safety efficacy buspirone treatment anxiety youth ( age 6-17 year ) autism spectrum disorder . The study result use generate hypothesis large randomize control clinical trial explicit hypotheses sufficient statistical power .</brief_summary>
	<brief_title>Double-blind Trial Buspirone Treatment Anxiety Youth With Autism Spectrum Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Male female participant 6 17 year age . Fulfills diagnosis autism spectrum disorder meet DSMIVTR PDD diagnostic criterion autistic disorder , Asperger 's disorder , PDDNOS establish clinical diagnostic interview . Participants score ≥60 Anxiety/Depression subscale Child Behavior Checklist ( CBCL ) CGIAnxiety severity ≥4 . Subjects psychotropic drug medication least 4 week prior initiate study treatment stable dose . Subjects disruptive behavior disorder , mood , psychosis allow participate study provide meet exclusionary criterion . Mental retardation ( I.Q . &lt; 70 ) DSMIVTR PDD diagnosis Rett 's disorder , childhood disintegrative disorder . History active seizure disorder ( EEG suggestive seizure activity and/or history seizure last 1 month ) . Subjects medical condition treatment either jeopardize subject safety affect scientific merit study , include : pregnant nursing female , organic brain disorder , uncorrected hypothyroidism hyperthyroidism , clinically significant abnormality ECG ( e.g . QT prolongation , arrhythmia ) , history renal hepatic impairment . Clinically unstable psychiatric condition judge serious suicidal risk . History substance abuse ( except nicotine caffeine ) within past 3 month urine drug screen positive substance abuse . Any concomitant medication primary central nervous system activity stable regimen &gt; 2 week . A nonresponder history intolerance buspirone , treatment adequate dose duration determine clinician .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Buspirone</keyword>
	<keyword>Buspar</keyword>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Pervasive Developmental Disorders</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Anxiety</keyword>
</DOC>